Auro Laboratories Limited (AUROLAB.BO)
INR 279.85
(-0.09%)
INR 279.85
(-0.09%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 188.07 Million | 32.81 Million | -65.9 Million | 128.15 Million | 93 Million | 68.7 Million |
| Net Income | 103.45 Million | 34.45 Million | 38.73 Million | 105.05 Million | 56.41 Million | 60.68 Million |
| Depreciation & Amortization | 10.92 Million | 10.74 Million | 10.17 Million | 10.35 Million | 10.23 Million | 10.09 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 63.78 Million | -22.96 Million | -120.68 Million | 9.78 Million | 20.15 Million | -9.19 Million |
| Other non-cash items | 9.9 Million | 10.57 Million | 5.86 Million | 2.95 Million | 6.19 Million | 7.12 Million |
| Investing Cash Flow | -386.7 Million | -50.81 Million | -53.42 Million | -35.07 Million | -22.07 Million | -31.86 Million |
| Investments in PPE | -356.4 Million | -40.74 Million | -46.09 Million | -3.75 Million | -6.72 Million | -16.15 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -30.96 Million | -10.07 Million | -7.33 Million | -31.32 Million | -15.35 Million | -15.71 Million |
| Financing Cash Flow | 190.94 Million | -81.78 Million | 97.92 Million | -4.55 Million | -55.16 Million | -18.26 Million |
| Debt repayment | -198.3 Million | -82.73 Million | -7.28 Million | -6.57 Million | -49.38 Million | -18.83 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 1000.00 | 947 Thousand | 105.2 Million | 2.01 Million | -5.77 Million | 569.63 Thousand |
| Accounts receivables | -9.87 Million | 12.08 Million | -63.14 Million | -15.19 Million | 27.23 Million | -1.28 Million |
| Accounts payables | - | -12.08 Million | 63.14 Million | 15.19 Million | -27.23 Million | 1.28 Million |
| Inventory | 35.16 Million | -75.01 Million | -17.07 Million | 15.15 Million | -6.88 Million | -18.82 Million |
| Other working capital | 91.25 Million | 52.04 Million | -103.6 Million | -5.36 Million | 27.04 Million | 9.63 Million |
| Cash at beginning of period | 24.17 Million | 123.95 Million | 145.36 Million | 56.84 Million | 41.07 Million | 22.5 Million |
| Cash at end of period | 16.48 Million | 24.17 Million | 123.95 Million | 145.36 Million | 56.84 Million | 41.07 Million |
| Capital Expenditure | -356.4 Million | -40.74 Million | -46.09 Million | -3.75 Million | -6.72 Million | -16.15 Million |
| Effect of forex changes on cash | - | -1000.00 | 1000.00 | - | - | - |
| Net cash flow / Change in cash | -7.68 Million | -99.78 Million | -21.4 Million | 88.52 Million | 15.76 Million | 18.57 Million |
| Free Cash Flow | -168.33 Million | -7.93 Million | -112 Million | 124.4 Million | 86.28 Million | 52.55 Million |
| Breakdown | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 103.45 Million | 23.82 Million | 27.34 Million | 19.68 Million | 7.07 Million | 34.45 Million |
| Depreciation & Amortization | 10.92 Million | - | - | - | - | 10.74 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 63.78 Million | - | - | - | - | -22.96 Million |
| Other non-cash items | 9.9 Million | -23.82 Million | -27.34 Million | -19.68 Million | -7.07 Million | 10.57 Million |
| Investing Cash Flow | -386.7 Million | - | - | - | - | -50.81 Million |
| Investments in PPE | -356.4 Million | - | - | - | - | -40.74 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -30.96 Million | - | - | - | - | -10.07 Million |
| Financing Cash Flow | 190.94 Million | - | - | - | - | -81.78 Million |
| Debt repayment | -198.3 Million | - | - | - | - | -82.73 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 1000.00 | - | - | - | - | 947 Thousand |
| Accounts receivables | -9.87 Million | - | - | - | - | 12.08 Million |
| Accounts payables | - | - | - | - | - | -12.08 Million |
| Inventory | 35.16 Million | - | - | - | - | -75.01 Million |
| Other working capital | 91.25 Million | - | - | - | - | 52.04 Million |
| Cash at beginning of period | 24.17 Million | - | - | - | - | 123.95 Million |
| Cash at end of period | 16.48 Million | - | - | - | - | 24.17 Million |
| Capital Expenditure | -356.4 Million | - | - | - | - | -40.74 Million |
| Effect of forex changes on cash | - | - | - | - | - | -1000.00 |
| Net cash flow / Change in cash | -7.68 Million | - | - | - | - | -99.78 Million |
| Free Cash Flow | -168.33 Million | - | - | - | - | -7.93 Million |
300030
300171
CMCXF
BZLFY
RGL
FAGI